Avalo Therapeutics CMO sells $20,000 in company stock

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, sold 1,000 shares of company stock for $20,000 on August 17, 2026, according to a SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan adopted in November 2025. Doyle also acquired 1,000 shares by exercising stock options at $12.65 per share, and now directly owns 51,776 shares. The stock trades near its 52-week high of $24.27, with an 83% return over the past year. Avalo recently joined the Russell 2000 and 3000 indexes, and analysts have issued positive ratings on its lead drug candidate.